AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02400593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Workshop
Description: Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
Study NCT01828892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
Study NCT01828892 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
Study NCT01828892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition
Study NCT01828892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutrition support
Description: Nutritional replacement and bowel rest via enteral or parenteral nutrition
Study NCT01457885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine/Busulfan x 4
Description: * Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days
Study NCT01457885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplant
Description: Peripheral blood stem cell transplant, after pre-conditioning drug treatment
Study NCT04668950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
Study NCT04668950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will take 2 capsules per day as tolerated for approximately 15 days
Study NCT01328860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow progenitor cells (BMPC) autologous transplantation
Description: Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
Study NCT02983383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block group (Group T)
Description: At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
Study NCT02983383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
Study NCT04637542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Learning
Description: The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods.
Study NCT01113762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: articular surface replacement ASR, DePuy
Description: posterolateral incision
Study NCT01113762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCap/Magnum modular head, Biomet
Description: posterolateral incision
Study NCT01113762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet
Description: posterolateral incision
Study NCT01113762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)
Description: posterolateral incision
Study NCT01548612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
Study NCT01548612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose solution
Description: Intravenous infusion of glucose solution 5% for 240 minutes
Study NCT00901758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Nitroglycerin
Description: IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
Study NCT00901758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study NCT03511612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measure ankle brachial index (ABI)
Description: This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
Study NCT04196946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mcg fentanyl
Description: Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
Study NCT04196946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mcg alfentanil
Description: Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
Study NCT01533662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine infusion
Description: patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
Study NCT01533662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: patients receiving saline infusion
Description: patients more than 60 years receiving 100micrograms of saline infusion
Study NCT05687825 — intervention group
Intervention type: PROCEDURE
Intervention: pancreaticoduodenectomy procedure
Description: Pancreaticoduodenectomy operation
Study NCT03276286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nativis Voyager
Description: Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
Study NCT02400593 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meditation Workshop
Description: Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
Study NCT02402985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High animal protein diet group
Description: 25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
Study NCT02402985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High plant protein diet group
Description: 25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
Study NCT03747965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesothelin-directed CAR-T cells
Description: Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
Study NCT03591016 — intervention group
Intervention type: OTHER
Intervention: Recording number of IV attempts
Description: Recording number of IV attempts in the operating room
Study NCT02950077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based stress reduction
Description: The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
Study NCT01386736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D drops
Description: Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
Study NCT01386736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
Study NCT02453763 — intervention group
Intervention type: DEVICE
Intervention: Transcranial direct current stimulation
Description: All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
Study NCT02453763 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
Study NCT05525156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin enteric coated tablet 75 mg
Description: blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
Study NCT05525156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin enteric coated tablet 75 mg
Description: blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
Study NCT00733746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: oral administration
Study NCT00733746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Intravenous administration
Study NCT00733746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT02169765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic resection
Description: Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
Study NCT02169765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed in less than one week after clinical diagnosis.
Study NCT02255201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Master Performance Blend Dose 1
Description: Caffeine content: 200 mg
Study NCT02255201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Master Performance Blend Dose 2
Description: Caffeine content: 400 mg
Study NCT02255201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Performance Energy Blend
Description: Caffeine content: 175 mg
Study NCT02255201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Blend
Description: Caffeine content: 200 mg
Study NCT02255201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caffeine content: 0 mg
Study NCT01073852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, 1 pill orally twice daily for 9 weeks.
Study NCT01073852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Patients will be taking hydroxychloroquine 200mg orally twice/daily.
Study NCT02191228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin - single dose
Study NCT01969032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
Description: Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
Study NCT05698953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
Study NCT05698953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
Study NCT01681524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurpiridaz F18
Description: Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
Study NCT02277119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maestro
Description: OCT machines used for diagnostic purposes
Study NCT02277119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iVue
Description: OCT machines used for diagnostic purposes
Study NCT02191228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin - Multiple dose
Study NCT04162028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebutlized Ketamine
Description: The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
Study NCT04401696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing.
Study NCT04401696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Oxygen
Description: The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
Study NCT04643262 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
Study NCT01770561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated sensor and infusion set.
Description: Change patients from current devices to the Integrated sensor and infusion set.
Study NCT05200754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent/Vaccine-boosted Plasma (CP/PVP)
Description: Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion.
Study NCT04318782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic thrombectomy
Description: Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
Study NCT02506504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory help then sham ventilation
Description: The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
Study NCT02506504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham ventilation then Inspiratory help
Description: The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
Study NCT02943733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Anti-metabolite agent, taken orally.
Study NCT02943733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapy drug.
Study NCT02943733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study NCT02943733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study NCT01712256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Study NCT01599507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: TIW dosing, capsule
Study NCT01599507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TIW dosing, capsule
Study NCT02259309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol - buccal
Description: buccal administration
Study NCT02259309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol - vaginal
Description: vaginal administration
Study NCT00965822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: North American ginseng
Description: 3 day, once daily, dosing
Study NCT00965822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 day, once daily dosing
Study NCT02202733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cooking
Description: The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
Study NCT02196792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Poly liner
Description: E-Poly liner with a titanium cup
Study NCT02196792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArComXL liner
Description: ArComXL liner with a titanium cup
Study NCT03119428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-313M32
Description: OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Study NCT03119428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human IgG4 anti-PD-1 monoclonal antibody
Study NCT01735942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate
Study NCT01735942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Study NCT02146625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-40002